<DOC>
	<DOCNO>NCT00096200</DOCNO>
	<brief_summary>Sorafenib may stop growth tumor cell block enzymes necessary growth stop blood flow tumor . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop tumor cell divide stop grow die . Giving sorafenib together chemotherapy may kill tumor cell . This randomized phase II trial study well give sorafenib together paclitaxel carboplatin work treat patient recurrent ovarian cancer , primary peritoneal cancer , fallopian tube cancer . ( Sorafenib group close 10/10/2008 ) .</brief_summary>
	<brief_title>Sorafenib With Without Paclitaxel Carboplatin Treating Patients With Recurrent Ovarian Cancer , Primary Peritoneal Cancer , Fallopian Tube Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare progression-free overall survival rate patient recurrent platinum-sensitive ovarian epithelial , primary peritoneal , fallopian tube cancer treat sorafenib without carboplatin paclitaxel . ( Arm I [ sorafenib ] close accrual 10/01/2008 ) II . Evaluate response rate time disease progression patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord performance status participate center . ARM I ( close accrual 10/01/2008 ) : Patients receive oral sorafenib twice daily day 1-28.Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients disease progression crossover arm II . ARM II : Patients receive oral sorafenib twice daily day 2-19 . Patients also receive carboplatin IV 30 minute paclitaxel IV 3 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Diagnosis ovarian epithelial , primary peritoneal , fallopian tube cancer Recurrent disease Must receive prior platinumbased regimen Platinumsensitive ( treatmentfree interval &gt; 6 month ) No 2 prior chemotherapy regimens Measurable disease At least 1 unidimensionally measurable lesion &gt; = 20 mm conventional technique OR &gt; = 10 mm spiral CT scan Not prior irradiation field No known brain metastasis Performance status : ECOG 02 OR Karnofsky 80100 % Life expectancy : More 12 week Hematopoietic : Absolute neutrophil count &gt; = 1,500/mm3 Platelet count &gt; = 100,000/mm3 Hemoglobin &gt; = 9 g/dL No bleeding diathesis Hepatic : Bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT = &lt; 2 time ULN No history allergic reaction attribute compound similar chemical biological composition sorafenib agent use study Patients reaction taxane platinum yet rechallenged may undergo desensitization regimen study No hypersensitivity paclitaxel drug use vehicle Cremophor El : Prior hypersensitivity reaction paclitaxel allow provide rechallenged successfully Renal : Creatinine &lt; 2 mg/dL Cardiovascular : Abnormal cardiac conduction ( e.g. , bundle branch block heart block ) allow stable past 6 month No symptomatic congestive heart failure No uncontrolled hypertension No cardiac arrhythmia No unstable angina pectoris ; No myocardial infarction within past 6 month Negative pregnancy test Fertile patient must use effective contraception Adequate intestinal function No concurrent requirement IV hydration nutritional support No active ongoing infection No psychiatric illness social situation would preclude study compliance No concurrent uncontrolled illness No invasive malignancy past 5 year except nonmelanoma skin cancer More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover More 3 week since prior hormonal therapy More 4 week since prior radiotherapy recover No prior sorafenib No prior anticancer therapy contraindicates study therapy No concurrent cytochrome P450 enzymeinducing antiepileptic drug ( phenytoin , carbamazepine , phenobarbital ) , rifampin , Hypericum perforatum ( St. John 's wort ) No concurrent combination antiretroviral therapy HIVpositive patient No concurrent therapeutic anticoagulation therapy Concurrent prophylactic lowdose warfarin allow maintenance venous arterial access device No concurrent anticancer therapies No concurrent investigational agent Not pregnant nursing</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>